Literature DB >> 19342665

A protective role for dengue virus-specific CD8+ T cells.

Lauren E Yauch1, Raphaël M Zellweger, Maya F Kotturi, Afrina Qutubuddin, John Sidney, Bjoern Peters, Tyler R Prestwood, Alessandro Sette, Sujan Shresta.   

Abstract

Infection with one of the four serotypes of dengue virus (DENV1-4) can result in a range of clinical manifestations in humans, from dengue fever to the more serious dengue hemorrhagic fever/dengue shock syndrome. Although T cells have been implicated in the immunopathogenesis of secondary infections with heterologous DENV serotypes, the role of T cells in protection against DENV is unknown. In this study, we used a mouse-passaged DENV2 strain, S221, to investigate the role of CD8(+) T cells in the immune response to primary DENV infection. S221 did not replicate well in wild-type mice, but did induce a CD8(+) T cell response, whereas viral replication and a robust CD8(+) T cell response were observed after infection of IFN-alpha/betaR(-/-) mice. Depletion of CD8(+) T cells from IFN-alpha/betaR(-/-) mice before infection resulted in significantly higher viral loads compared with undepleted mice. Mapping the specificity of the CD8(+) T cell response led to the identification of 12 epitopes derived from 6 of the 10 DENV proteins, with a similar immunodominance hierarchy observed in wild-type and IFN-alpha/betaR(-/-) mice. DENV-specific CD8(+) T cells produced IFN-gamma, TNF-alpha, expressed cell surface CD107a, and exhibited cytotoxic activity in vivo. Finally, immunization with four of the immunodominant CD8(+) T cell epitopes enhanced viral clearance. Collectively, our results reveal an important role for CD8(+) T cells in the host defense against DENV and demonstrate that the anti-DENV CD8(+) T cell response can be enhanced by immunization, providing rationale for designing DENV-specific vaccines that induce cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342665      PMCID: PMC2674070          DOI: 10.4049/jimmunol.0801974

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Infection of human cells by dengue virus is modulated by different cell types and viral strains.

Authors:  M S Diamond; D Edgil; T G Roberts; B Lu; E Harris
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever.

Authors:  Sharone Green; Alan Rothman
Journal:  Curr Opin Infect Dis       Date:  2006-10       Impact factor: 4.915

Review 3.  Dengue.

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

Review 4.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

5.  Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

Authors:  M S Diamond; T G Roberts; D Edgil; B Lu; J Ernst; E Harris
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  Unusual neurologic manifestations occurring during dengue fever infection.

Authors:  O Patey; L Ollivaud; J Breuil; C Lafaix
Journal:  Am J Trop Med Hyg       Date:  1993-06       Impact factor: 2.345

7.  T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?

Authors:  Juthathip Mongkolsapaya; Thaneeya Duangchinda; Wanwisa Dejnirattisai; Sirijit Vasanawathana; Panisadee Avirutnan; Aroonroong Jairungsri; Nuanpan Khemnu; Nattaya Tangthawornchaikul; Pojchong Chotiyarnwong; Kanokwan Sae-Jang; Michael Koch; Yvonne Jones; Andrew McMichael; Xiaoning Xu; Prida Malasit; Gavin Screaton
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

8.  Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; M Aguet; R M Zinkernagel
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes.

Authors:  Allison Imrie; Janet Meeks; Alexandra Gurary; Munkhzul Sukhbataar; Paul Kitsutani; Paul Effler; Zhengshan Zhao
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

10.  Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.

Authors:  P G Livingston; I Kurane; L C Dai; Y Okamoto; C J Lai; R Men; S Karaki; M Takiguchi; F A Ennis
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

View more
  171 in total

1.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

3.  The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.

Authors:  Iris Valdés; Lázaro Gil; Yaremis Romero; Jorge Castro; Pedro Puente; Laura Lazo; Ernesto Marcos; María G Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

4.  Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice.

Authors:  Annie Elong Ngono; Edward A Vizcarra; William W Tang; Nicholas Sheets; Yunichel Joo; Kenneth Kim; Matthew J Gorman; Michael S Diamond; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2017-01-11       Impact factor: 21.023

5.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination.

Authors:  Lauren E Yauch; Tyler R Prestwood; Monica M May; Malika M Morar; Raphaël M Zellweger; Bjoern Peters; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

7.  Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.

Authors:  Haiyan Chu; Subash C Das; Jeremy F Fuchs; M Suresh; Scott C Weaver; Dan T Stinchcomb; Charalambos D Partidos; Jorge E Osorio
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

8.  The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus.

Authors:  Hui-Wen Chen; Kevin King; Jui Tu; Marisa Sanchez; Andrew D Luster; Sujan Shresta
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

9.  Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Authors:  Emilie Branche; William Weihao Tang; Karla M Viramontes; Matthew Perry Young; Nicholas Sheets; Yunichel Joo; Anh-Viet T Nguyen; Sujan Shresta
Journal:  Antiviral Res       Date:  2018-07-30       Impact factor: 5.970

10.  Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

Authors:  Laura Rivino; Emmanuelle A P Kumaran; Vojislav Jovanovic; Karen Nadua; En Wei Teo; Shyue Wei Pang; Guo Hui Teo; Victor Chih Hao Gan; David C Lye; Yee Sin Leo; Brendon J Hanson; Kenneth G C Smith; Antonio Bertoletti; David M Kemeny; Paul A MacAry
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.